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10-year outcome of the Thoracic Endovascular
Aortic Repair (TEVAR) Procedure
Jacob Fink, Youssef Zaki, Dr. Timothy Misselbeck M.D. and Dr. James Wu M.D.
Department of Cardiothoracic Surgery

Lehigh Valley Health Network, Allentown, Pennsylvania

OVERVIEW

OUTCOMES

RESULTS

• Purpose: The goal of the study was to assess the positive and
negative outcomes of the TEVAR procedure in hopes of identifying
recurrent issues.

• 51 of the patients survived and 25 of them died
• A total of 2 patients (8%) experienced TEVAR related deaths . One patient died
during surgery while another patient died post-operatively due to a faulty graft
and subsequent aneurysm.
• Of the 76 patients 58 (76.32%) of them did not experience a complication at
time of follow-up.
• A total of 13 patients, around 25%, did report a shrinkage of their aneurysm at
time of follow-up. At time of follow-up 39 (75%) did not report a shrinkage.
Also, 24 of the patients had a unknown size of their aneurysm post-operatively.
• In the Kaplan-Meier curve as the years increase the survival probability
decreases. So, at 5 years post-operatively the median survival is 50%.
• Of the 18 (23.68) patients who did experience a complication 10 (13.16%) of
them survived and 8 (10.53%)of them died.
• 1 patient out of the 76 patients experienced right hemiplegia and subsequent
death 5 months after the procedure, and 1 patient experienced weakness in
the lower body

• TEVAR has been FDA approved and implemented at Lehigh Valley
Health Network (LVHN) since 2006.
• TEVAR is used to treat aneurysms and dissections in the descending
aorta and/or the aortic arch1. The Cardiothoracic surgeon accesses
the aorta via the femoral artery. This is referred to as the Transfemoral
(TF) approach and is the preferred method, although other methods
of access are sometimes implemented. Several catheters are guided
through the arteries to the aortic aneurysm/dissection. The catheters
and stent are monitored using X-rays and ultrasounds. Once the stent
is positioned properly, it is deployed (expanded) to fit the aorta and
act as a new vessel through which blood can flow2. The aneurysm will
eventually shrink in the most successful cases.

METHODS & DEMOGRAPHICS
• This was a retrospective study that included 80 procedures
performed on 76 patients at LVHN. The interval of study was from
April 2006 to March 2016.
• Patients were followed-up with post-operatively in the Cardiothoracic
office. CT scans were performed at the time of each follow-up in
order to check the status of the graft implant.
• Data collection for this study consisted of reviewing the CT scan
report at each follow-up and recording any complications with the
graft or lack thereof.
– Complications include leakage or migration of the graft implant3

DEMOGRAPHICS OF TEVAR PATIENTS
Number of Patients (n)

N = 76

Age (Years), Range

Mean Age = 83, Range = (18 – 88)

Sex (Male or Female)

Male = 46 Female = 30

• Table 2: representing the variables analyzed in this study and their results

Table 2: Comorbidities
•
•
•
•
•
•
•

Hypertension – 80.26% (61/76)
Obesity – 17.11% (13/76)
Diabetes – 14.47% (11/76)
Kidney Disease – (acute 9.21%), (chronic 15.79%), (kidney failure 2.63%)
Smoking history – 61.84% (47/76)
Readmission within 90 days – 36.84% (28/76)
Aneurysm shrinkage – 25% (13/76)

• Kaplan Meier curve representing if a patient has a TEVAR complication, there
survival probability
Table 3: Patient status at time of follow-up

What was the patient's status at the time of follow-up

Survival(Did the patient survive?)

Frequency
Percent
Dead

Survival

Total

Did Not Experience TEVAR Complication by the End of Follow-up

17
22.37
29.31
68.00

41
53.95
70.69
80.39

58
76.32

Experienced TEVAR Complication

8
10.53
44.44
32.00

10
13.16
55.56
19.61

18
23.68

Total

25
32.89

51
67.11

76
100.00

• Table 3: representing patients status at time of follow-up
• Table 4: Patients experiencing neurological complications post-operatively

Table 4: Neurological Complications
• Hemiparesis – 1.40% (1/76)
• Weakness of the lower extremities – 1.40% (1/76)

CONCLUSIONS
TEVAR is well tolerated in a patient population with high co-morbid
conditions. Ten out of eighteen of the patients who did experience a
complication during follow-up experienced it within two years postoperatively of the procedure. LVHN or the manufacturers should look into a
better implantation method or device material that better suits the needs of
the patient. The data shows that the patients who did not experience
complications had a higher chance of survival. Patients and LVHN should
minimize risk factors that contribute to post-operative problems. (Obesity,
Smoking, etc.). Also, patients should make sure to follow-up with their
physician well after the procedure has been completed.
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